Sitemap

Marketing Authorisation Holder

Marketing Authorisation

Market exclusivity

MAMS

Malignant

MAH

MABEL

MA

LY

LTP

Low-intervention clinical trial

Log-rank test

Live-attenuated vaccine

Lifetime prevalence

Life Years Gained

Legally Authorised Representative

Lead-time Bias

LAR

ITT

Investigator’s Brochure

Investigator

Investigational plan

Investigational Medicinal Product Dossier

Investigational Medicinal Product

Intravenous

Interventional Study

Intervention

International Non-proprietary Name

International Council for Harmonisation

Internal Validity

Intermediate endpoint

Interim analysis

Intention-to-treat

Innovative characteristics

INN

Informed Consent

Indication

Inclusion Criteria

Incidence

Inactivated vaccine

IMPD

Impartial Witness

IMP

Immunotoxicity

Immunogenic

Idiosyncratic drug reaction

Identified risk

ICH

IB

Hypothesis testing

Hypothesis

HTA

HRQoL

HIV

Heterogeneity

hERG

Herd immunity

Health-Related Quality of Life

Health Technology Assessment

Health event

Hazard ratio

Hard Endpoint

Half life

GWIS

GWAS

GWA

GVP

Guarantee-time bias

Group sequential design

Good Pharmacovigilance Practices

Good Manufacturing Practice

Good Laboratory Practice

Good Distribution Practice

Good Clinical Practice

Gold Standard

GMP

GMO

GLP

Genotyping

Genotype

Genotoxin

Genotoxicity Study

Genomics

Genomic technologies

Genomic Marker

Genome-wide inferred study

Genome-wide association study

Genome

Genetically Modified Organism

Generic Medicine

Gene Therapy

Gene Mutation

GDPR

GDP

GCP

Gamete

Futility

Freeze-drying

Fraud

Formulation

Extractables

Exploratory trials

Exclusion Criteria

Excipient

Evidence-based Medicine

European Public Assessment Report

EuroBioBank

EUnetHTA

EU Regulation

Ethics Committee

Ethical Principles

Equity considerations

Epigenomics

Epigenetics

EPAR

Endpoint

Endocrine Therapy

Eligibility

Efficiency

Efficacy

Effectiveness

EC

EBM

DSUR

DSMB

Drug tolerance

Drug substance

Drug distribution

Drug development

Drug candidate

Double blind

Dose-ranging

Dose

Dosage regimen

Dosage forms

Dosage

Disease burden

Disability-adjusted life year

Directive

Developmental and reproductive toxicity

Development Safety Update Report

Delivery system

Delivery device

Degradants

Decentralised procedure

Dear Doctor letter

Data Mining

Data Merging

Data Manipulation

Data exclusivity

1 2 3 … 1,550 Next »